Simon R Lord
Simon R Lord
Verified email at
Cited by
Cited by
Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation
K Bensaad, E Favaro, CA Lewis, B Peck, S Lord, JM Collins, KE Pinnick, ...
Cell reports 9 (1), 349-365, 2014
Imaging tumour hypoxia with positron emission tomography
IN Fleming, R Manavaki, PJ Blower, C West, KJ Williams, AL Harris, ...
British journal of cancer 112 (2), 238-250, 2015
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ...
The Lancet Oncology 20 (8), 1124-1135, 2019
Gene expression and hypoxia in breast cancer
E Favaro, S Lord, AL Harris, FM Buffa
Genome medicine 3 (8), 1-12, 2011
Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer
SR Lord, WC Cheng, D Liu, E Gaude, S Haider, T Metcalf, N Patel, ...
Cell metabolism 28 (5), 679-688. e4, 2018
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
M Morotti, E Bridges, A Valli, H Choudhry, H Sheldon, S Wigfield, N Gray, ...
Proceedings of the National Academy of Sciences 116 (25), 12452-12461, 2019
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.
C Saura, F Thistlethwaite, U Banerji, S Lord, V Moreno, I MacPherson, ...
Journal of Clinical Oncology 36 (15_suppl), 1014-1014, 2018
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
PS Hall, SR Lord, M Collinson, H Marshall, M Jones, C Lowe, H Howard, ...
British journal of cancer 116 (4), 472-478, 2017
Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal …
PS Hall, D Swinson, DA Cairns, JS Waters, R Petty, C Allmark, S Ruddock, ...
JAMA oncology 7 (6), 869-877, 2021
Radiogenomics monitoring in breast cancer identifies metabolism and immune checkpoints as early actionable mechanisms of resistance to anti-angiogenic treatment
S Mehta, NP Hughes, S Li, A Jubb, R Adams, S Lord, L Koumakis, ...
EBioMedicine 10, 109-116, 2016
Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014; 9 (1): 349–65
K Bensaad, E Favaro, CA Lewis, B Peck, S Lord, JM Collins, KE Pinnick, ...
Epub 2014/09/30. https://doi. org/10.1016/j. celrep. 2014.08. 056 PMID: 25263561, 0
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
GI Shapiro, R Wesolowski, C Devoe, S Lord, J Pollard, BS Hendriks, ...
British journal of cancer 125 (4), 520-527, 2021
Angiogenesis-still a worthwhile target for breast cancer therapy?
S Lord, AL Harris
Breast Cancer Research 12 (4), 1-4, 2010
Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy
SR Lord, PS Hall, P McShane, J Brown, MT Seymour
Clinical Oncology 22 (2), 107-113, 2010
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin
SR Lord, JM Collins, WC Cheng, S Haider, S Wigfield, E Gaude, ...
British journal of cancer 122 (2), 258-265, 2020
Neoadjuvant window studies of metformin and biomarker development for drugs targeting cancer metabolism
SR Lord, N Patel, D Liu, J Fenwick, F Gleeson, F Buffa, AL Harris
Journal of the National Cancer Institute Monographs 2015 (51), 81-86, 2015
First-in-human phase I study of MP0250, a first-in-class DARPin drug candidate targeting VEGF and HGF, in patients with advanced solid tumors
RD Baird, C Linossi, M Middleton, S Lord, A Harris, J Rodón, C Zitt, ...
Journal of Clinical Oncology 39 (2), 145, 2021
Window of opportunity clinical trial designs to study cancer metabolism
F Aroldi, SR Lord
British journal of cancer 122 (1), 45-51, 2020
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+ paclitaxel (P), and …
P Schmid, SA Im, A Armstrong, YH Park, WP Chung, Z Nowecki, S Lord, ...
Journal of Clinical Oncology 39 (15_suppl), 1023-1023, 2021
Non-cancer medications for patients with incurable cancer: time to stop and think?
PS Hall, SR Lord, A El-Laboudi, MT Seymour
British Journal of General Practice 60 (573), 243-244, 2010
The system can't perform the operation now. Try again later.
Articles 1–20